Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Straten PT, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Feb;566(7745):E13. doi: 10.1038/s41586-019-0959-z.

PMID:
30733620
2.

Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19. Erratum in: Nature. 2019 Feb;566(7745):E13.

PMID:
30568303
3.

RNA editing derived epitopes function as cancer antigens to elicit immune responses.

Zhang M, Fritsche J, Roszik J, Williams LJ, Peng X, Chiu Y, Tsou CC, Hoffgaard F, Goldfinger V, Schoor O, Talukder A, Forget MA, Haymaker C, Bernatchez C, Han L, Tsang YH, Kong K, Xu X, Scott KL, Singh-Jasuja H, Lizee G, Liang H, Weinschenk T, Mills GB, Hwu P.

Nat Commun. 2018 Sep 25;9(1):3919. doi: 10.1038/s41467-018-06405-9.

4.

Translating Immunopeptidomics to Immunotherapy-Decision-Making for Patient and Personalized Target Selection.

Fritsche J, Rakitsch B, Hoffgaard F, Römer M, Schuster H, Kowalewski DJ, Priemer M, Stos-Zweifel V, Hörzer H, Satelli A, Sonntag A, Goldfinger V, Song C, Mahr A, Ott M, Schoor O, Weinschenk T.

Proteomics. 2018 Jun;18(12):e1700284. doi: 10.1002/pmic.201700284. Epub 2018 Apr 10.

5.

A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma.

Rampling R, Peoples S, Mulholland PJ, James A, Al-Salihi O, Twelves CJ, McBain C, Jefferies S, Jackson A, Stewart W, Lindner J, Kutscher S, Hilf N, McGuigan L, Peters J, Hill K, Schoor O, Singh-Jasuja H, Halford SE, Ritchie JW.

Clin Cancer Res. 2016 Oct 1;22(19):4776-4785. Epub 2016 May 25.

6.

Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy.

Neidert MC, Schoor O, Trautwein C, Trautwein N, Christ L, Melms A, Honegger J, Rammensee HG, Herold-Mende C, Dietrich PY, Stevanović S.

J Neurooncol. 2013 Feb;111(3):285-94. doi: 10.1007/s11060-012-1028-8. Epub 2012 Dec 23.

PMID:
23263746
7.

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.

Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H.

Nat Med. 2012 Aug;18(8):1254-61. doi: 10.1038/nm.2883. Epub 2012 Jul 29.

PMID:
22842478
8.

Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy.

Dutoit V, Herold-Mende C, Hilf N, Schoor O, Beckhove P, Bucher J, Dorsch K, Flohr S, Fritsche J, Lewandrowski P, Lohr J, Rammensee HG, Stevanovic S, Trautwein C, Vass V, Walter S, Walker PR, Weinschenk T, Singh-Jasuja H, Dietrich PY.

Brain. 2012 Apr;135(Pt 4):1042-54. doi: 10.1093/brain/aws042. Epub 2012 Mar 14.

PMID:
22418738
9.

A cryptic vascular endothelial growth factor T-cell epitope: identification and characterization by mass spectrometry and T-cell assays.

Weinzierl AO, Maurer D, Altenberend F, Schneiderhan-Marra N, Klingel K, Schoor O, Wernet D, Joos T, Rammensee HG, Stevanović S.

Cancer Res. 2008 Apr 1;68(7):2447-54. doi: 10.1158/0008-5472.CAN-07-2540.

10.

Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface.

Weinzierl AO, Lemmel C, Schoor O, Müller M, Krüger T, Wernet D, Hennenlotter J, Stenzl A, Klingel K, Rammensee HG, Stevanovic S.

Mol Cell Proteomics. 2007 Jan;6(1):102-13. Epub 2006 Oct 29.

11.

Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas.

Dengjel J, Nastke MD, Gouttefangeas C, Gitsioudis G, Schoor O, Altenberend F, Müller M, Krämer B, Missiou A, Sauter M, Hennenlotter J, Wernet D, Stenzl A, Rammensee HG, Klingel K, Stevanović S.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4163-70.

12.

Autophagy in innate and adaptive immunity against intracellular pathogens.

Schmid D, Dengjel J, Schoor O, Stevanovic S, Münz C.

J Mol Med (Berl). 2006 Mar;84(3):194-202. Epub 2006 Jan 28. Review.

PMID:
16501849
13.

Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas.

Carralot JP, Weide B, Schoor O, Probst J, Scheel B, Teufel R, Hoerr I, Garbe C, Rammensee HG, Pascolo S.

Genet Vaccines Ther. 2005 Aug 22;3:6.

14.

MAGED4-expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue.

Krämer BF, Schoor O, Krüger T, Reichle C, Müller M, Weinschenk T, Hennenlotter J, Stenzl A, Rammensee HG, Stevanovic S.

Cancer Biol Ther. 2005 Sep;4(9):943-8. Epub 2005 Sep 8.

PMID:
16082191
15.

Autophagy promotes MHC class II presentation of peptides from intracellular source proteins.

Dengjel J, Schoor O, Fischer R, Reich M, Kraus M, Müller M, Kreymborg K, Altenberend F, Brandenburg J, Kalbacher H, Brock R, Driessen C, Rammensee HG, Stevanovic S.

Proc Natl Acad Sci U S A. 2005 May 31;102(22):7922-7. Epub 2005 May 13.

16.

Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding.

Tenzer S, Peters B, Bulik S, Schoor O, Lemmel C, Schatz MM, Kloetzel PM, Rammensee HG, Schild H, Holzhütter HG.

Cell Mol Life Sci. 2005 May;62(9):1025-37.

PMID:
15868101
17.

CD8+ T cells specific for a potential HLA-A*0201 epitope from Chlamydophila pneumoniae are present in the PBMCs from infected patients.

Carralot JP, Dumrese C, Wessel R, Riessen R, Autenrieth I, Walter S, Schoor O, Stevanovic S, Rammensee HG, Pascolo S.

Int Immunol. 2005 May;17(5):591-7. Epub 2005 Mar 31.

PMID:
15802306
18.

Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways.

Appel S, Rupf A, Weck MM, Schoor O, Brümmendorf TH, Weinschenk T, Grünebach F, Brossart P.

Clin Cancer Res. 2005 Mar 1;11(5):1928-40.

19.

Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy.

Krüger T, Schoor O, Lemmel C, Kraemer B, Reichle C, Dengjel J, Weinschenk T, Müller M, Hennenlotter J, Stenzl A, Rammensee HG, Stevanović S.

Cancer Immunol Immunother. 2005 Sep;54(9):826-36. Epub 2004 Dec 31.

PMID:
15627209
20.

The non-classical HLA class I molecule HFE does not influence the NK-like activity contained in fresh human PBMCs and does not interact with NK cells.

Pascolo S, Ginhoux F, Laham N, Walter S, Schoor O, Probst J, Rohrlich P, Obermayr F, Fisch P, Danos O, Ehrlich R, Lemonnier FA, Rammensee HG.

Int Immunol. 2005 Feb;17(2):117-22. Epub 2004 Dec 27.

PMID:
15623549
21.

Identification of a naturally processed cyclin D1 T-helper epitope by a novel combination of HLA class II targeting and differential mass spectrometry.

Dengjel J, Decker P, Schoor O, Altenberend F, Weinschenk T, Rammensee HG, Stevanovic S.

Eur J Immunol. 2004 Dec;34(12):3644-51. Erratum in: Eur J Immunol. 2005 Feb;35(2):666.

22.

A conserved sequence in the mouse variable T cell receptor alpha recombination signal sequence 23-bp spacer can affect recombination.

Probst J, Blumenthal SG, Tenzer S, Weinschenk T, Dittmer J, Schoor O, Six A, Rammensee HG, Pascolo S.

Eur J Immunol. 2004 Aug;34(8):2179-90.

23.

Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis.

Schmidt SM, Schag K, Müller MR, Weinschenk T, Appel S, Schoor O, Weck MM, Grünebach F, Kanz L, Stevanovic S, Rammensee HG, Brossart P.

Cancer Res. 2004 Feb 1;64(3):1164-70.

24.

Moderate degradation does not preclude microarray analysis of small amounts of RNA.

Schoor O, Weinschenk T, Hennenlotter J, Corvin S, Stenzl A, Rammensee HG, Stevanović S.

Biotechniques. 2003 Dec;35(6):1192-6, 1198-201.

25.

Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres.

Walter S, Herrgen L, Schoor O, Jung G, Wernet D, Bühring HJ, Rammensee HG, Stevanović S.

J Immunol. 2003 Nov 15;171(10):4974-8.

26.

Integrated functional genomics approach for the design of patient-individual antitumor vaccines.

Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, Kurek R, Loeser W, Bichler KH, Wernet D, Stevanović S, Rammensee HG.

Cancer Res. 2002 Oct 15;62(20):5818-27.

27.

Mechanical failures as a contributing cause to motor vehicle accidents South Africa.

van Schoor O, van Niekerk JL, Grobbelaar B.

Accid Anal Prev. 2001 Nov;33(6):713-21.

PMID:
11579973
28.

Exploratory study of the decongestive effect of Rhinopront syrup in adults and in children with acute rhinitis.

Lebacq E Jr, Gline JP, Joue P, Stockis A, Calderon P, Van Schoor O, Deroubaix X, Schwegler F.

Clin Trials Metaanal. 1994 Oct;29(2-3):113-24.

PMID:
10151073
29.

Daily chromium intake by infants in Belgium.

Deelstra H, van Schoor O, Robberecht H, Clara R, Eylenbosch W.

Acta Paediatr Scand. 1988 May;77(3):402-7.

PMID:
3389133
30.

Chromium and selenium levels in commercially available enteral nutrition.

Van Schoor OE, Robberecht HJ, De Leeuw I, Deelstra HA.

Z Lebensm Unters Forsch. 1985 Jan;180(1):26-9.

PMID:
3919512

Supplemental Content

Loading ...
Support Center